Gene Therapy in Hemophilia: A Transformational Patient Experience
| Autor: | Enayet Rasul, Ryan Hallock, Magnus Hellmann, Jay Konduros, Luke Pembroke, Gregory LeCleir, Jean Malacan PharmD, Sylvia von Mackensen PhD |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of Patient Experience, Vol 10 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2374-3743 23743735 |
| DOI: | 10.1177/23743735231193573 |
| Popis: | Hemophilia is a bleeding disorder caused by a single absent/defective gene and characterized by a lack of functional clotting factors. People with hemophilia may experience joint damage, pain, and psychological impairments, all of which could contribute to reduced health-related quality of life (HRQoL). The current standard of care is clotting factor replacement, which is associated with regular infusions; therefore, alternative treatments such as gene therapy (GT) are in development. GT involves the delivery of a functional copy of the clotting factor 8/9 gene by a single infusion into the patient's cells, enabling them to produce their own clotting factor VIII/IX. The impact of treatment on patients’ HRQoL can be assessed using hemophilia-specific patient-reported outcome (PRO) measures. Since these measures were designed before the advent of GT, there is a need for updated individualized PRO measures. Patient groups and regulatory authorities emphasize the need for increased patient engagement when considering clinical trial design. Here, we provide patients’ perspective on undergoing GT and discuss how to capture the patient voice when measuring the therapy's transformative impact. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|